Feel Therapeutics

Feel Therapeutics provides digital precision medicine for mental health, leveraging objective data and passive measurement through wearable technology and AI. The company's Digital Precision Medicine Platform continuously collects physiological, digital, and clinical data 24/7 from wearables, mobile phones, and clinician dashboards, using proprietary algorithms to compute biomarkers and metrics for mood, stress, sleep, psychomotor activity, and cognitive functioning. The platform offers solutions including Feel 360 for clinical trial monitoring, Feel RxPal for medication adherence, Feel DTx for precision digital therapeutics, and Feel RPM for remote patient monitoring. Feel Therapeutics has demonstrated 87% precision in detecting mood state changes and has published research in Nature Digital Medicine, with patents for emotion AI and digital biomarkers for ADHD, insomnia, and depression relapse. Now an IQVIA business, the company was founded in 2015 and headquartered in San Francisco, California, having raised approximately $30 million in Series A funding from investors including Satori Capital, SOSV, and Anthemis Group.